ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance
2024.08.26
Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products
2024.08.26
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024
2024.08.26
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2019-04-29
Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting
2019-03-12
FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively
2019-01-10
The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award
2018-10-30
Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics
2018-10-29
Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018
2018-08-22
Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China
2018-08-10
Group Turnover and Profit in the First Half of 2018 Increased 28.3%
2018-07-24
Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis
<
3
4
5
6
7
8
9
>